To validated the inhibitory effects of EZH2 inhibition, HCT116 colon cancer cells were treated with Tazemetostat (Taz, also known as EPZ‐6438), an FDA‐approved EZH2 inhibitor (EZH2i). The gene discussed is EZH2; the disease is colonic neoplasm.